Evaluate MMR protein status with the only companion diagnostic to identify endometrial cancer patients eligible for JEMPERLI^® (dostarlimab-gxly)

Roche Diagnostics is pleased to announce the U.S. FDA approval of VENTANA MMR RxDx panel as an aid in identifying patients eligible for treatment with the anti-PD1 immunotherapy JEMPERLI for MMR deficient endometrial carcinoma.

Endometrial cancer has been associated with genetic alterations, including MSI. Deficient MMR (dMMR) and MSI-High (MSI-H) is reported in 20-40% of cases. For this reason, NCCN guidelines recommend universal testing of endometrial carcinomas for MMR protein status.

Now your lab can help identify endometrial cancer patients eligible for JEMPERLI with the only Class III IHC panel available.